NEXN

Across TCGA pan-cancer cohorts, NEXN Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated NEXN data layer compared with 20 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher NEXN Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NEXN expression acts as an unfavorable survival marker.

LUAD, LUSC, and UCEC are the cancer types where NEXN Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	IV	0.342	0.893	<.001	22	view →
LUSC	OS	Median	All	0.180	0.660	.007	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

NEXN–LUAD (DFS)

Open the LUAD breakdown →